Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation and Depletion: 2023-2025

Historic Depreciation and Depletion for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $100,000.

  • Compass Therapeutics' Depreciation and Depletion fell 50.00% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year decrease of 42.86%. This contributed to the annual value of $600,000 for FY2024, which is 14.29% down from last year.
  • Per Compass Therapeutics' latest filing, its Depreciation and Depletion stood at $100,000 for Q3 2025, which was down 0.00% from $100,000 recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Depreciation and Depletion peaked at $200,000 during Q1 2023, and registered a low of $100,000 during Q3 2023.
  • Over the past 3 years, Compass Therapeutics' median Depreciation and Depletion value was $100,000 (recorded in 2025), while the average stood at $145,455.
  • The largest annual percentage gain for Compass Therapeutics' Depreciation and Depletion in the last 5 years was 100.00% (2024), contrasted with its biggest fall of 50.00% (2024).
  • Compass Therapeutics' Depreciation and Depletion (Quarterly) stood at $200,000 in 2023, then slumped by 50.00% to $100,000 in 2024, then tumbled by 50.00% to $100,000 in 2025.
  • Its Depreciation and Depletion stands at $100,000 for Q3 2025, versus $100,000 for Q2 2025 and $100,000 for Q1 2025.